SEARCH

SEARCH BY CITATION

References

  • 1
    Todo S, Demetris AJ, Van Thiel D, Teperman L, Fung JJ, Starzl TE. Orthotopic liver transplantation for patients with hepatitis B virus related liver disease. Hepatology 1991; 13: 619626.
  • 2
    O'Grady JG, Smith HM, Davies SE, Daniels HM, Donaldson PT, Tan KC, et al. Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications. J Hepatol 1992; 14: 104111.
  • 3
    Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP, Bismuth H. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329: 18421847.
  • 4
    Shouval D, Samuel D. Hepatitis B immune globulin to prevent HBV graft reinfection following liver transplantation: A concise review. Hepatology 2000; 32: 11891195.
  • 5
    Yao FY, Terrault NA, Freise C, Maslow L, Bass NM. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: A comparative study using a matched, untreated cohort. Hepatology 2001; 34: 411416.
  • 6
    Fontana R, Hann H, Perrillo R, Vierling JM, Wright T, Rakela J, et al. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology 2002; 123: 719727.
  • 7
    Schiff ER, Lai CL, Hadziyannis S, Neuhaus P, Terrault N, Colombo M, et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 2003; 38: 14191427.
  • 8
    Perrillo R, Rakela J, Dienstag J, Levy G, Martin P, Wright T, et al. Multicenter study of lamivudine therapy for Hepatitis B after liver transplantation. Lamivudine Transplant Group. Hepatology 1999; 29: 15811586.
  • 9
    Neff GW, O'Brien C, Nerry J, Shire N, Montalbano M, Ruiz P, et al. Outcomes in liver transplant recipients with hepatitis B virus: Resistance and recurrence patterns from a large transplant center over the last decade. Liver Transpl 2004; 10: 13721378.
  • 10
    Markowitz JS, Martin P, Conrad AJ, Markmann JF, Seu P, Yersiz H, et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998; 28: 585589.
  • 11
    Rosenau J, Bahr M, Tillmann HL, Trautwein C, Klempnauer J, Manns MP, Boker KM. Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation. Possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection. J Hepatol 2001; 34: 895902.
  • 12
    Marzano A, Salizzoni M, Debernardi-Venon W, Smedile A, Franchello A, Ciancio A, et al. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol 2001; 34: 903910.
  • 13
    Angus PW, McCaughan GW, Gane EJ, Crawford DH, Harley H. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl 2000; 6: 429433.
  • 14
    Han SH, Ofman J, Holt C, King K, Kunder G, Chen P, et al. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl 2001; 6: 741748.
  • 15
    Steinmuller T, Seehofer D, Rayes N, Muller AR, Settmacher U, Jonas S, et al. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology 2002; 35: 15281535.
  • 16
    Kim WR, Poterucha JJ, Kremers WK, Ishitani MB, Dickson ER. Outcome of liver transplantation for hepatitis B in the United States. Liver Transpl 2004; 10: 968974.
  • 17
    Trautwein C, Schrem H, Tillmann HL, Kubicka S, Walker D, Boker KH, et al. Hepatitis B virus mutations in the pre-S genome before and after liver transplantation. Hepatology 1996: 24: 482488.
  • 18
    Terrault NA, Zhou S, McCory RW, Pruett TL, Lake JR, Roberts JP, et al. Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin. Hepatology 1998, 28: 555561.
  • 19
    Perrillo RP, Wright T, Rakela J, Levy G, Schiff E, Gish R, et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after transplantation for chronic hepatitis B. Hepatology 2001; 33: 424432.
  • 20
    Bock CT, Tillmann HL, Torresi J, Klempnauer J, Locarnini S, Manns MP, Trautwein C. Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. Gastroenterology 2002; 122: 264273.
  • 21
    Brind A, Jiang JJ, Samuel D, Gigou M, Feray C, Brechot C, Kremsdorf D. Evidence for selection of hepatitis B mutants after liver transplantation through peripheral blood mononuclear cell infection. J Hepatol 1997; 26: 228235.
  • 22
    Samuel D, Bismuth A, Mathieu D, Arulnaden JL, Reynes M, Benhamou JP, et al. Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients. Lancet 1991; 337: 813815.
  • 23
    Lauchart W, Muller R, Pichlmayr R. Long-term immunoprophylaxis of hepatitis B virus reinfection in recipients of human liver allografts. Transplant Proc 1987; 19: 40514053.
  • 24
    Roche B, Feray C, Gigou M, Roque-Afonso AM, Arulnaden JL, Delvart V, et al. HBV DNA persistence 10 years after liver transplantation despite successful anti-HBs passive immunoprophylaxis. Hepatology 2003: 38: 8695.
  • 25
    Terrault NA, Zhou S, Combs C, Hahn JA, Lake JR, Roberts JP, et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulins. Hepatology 1996; 24: 13271333.
  • 26
    Sawyer RG, McGory RW, Gaffey MJ, McCullough C, Shephard E, Houlgrave C, et al. Improved clinical outcome with liver transplantation for hepatitis B related cirrhosis. Ann Surg 1998: 227: 841850.
  • 27
    Devlin J, Smith HM, O'Grady JG, Portmann B, Tan KC, Williams R. Impact of immunoprophylaxis and patient selection on outcome of transplantation for HBsAg-positive liver recipients. J Hepatol 1994; 21: 204210.
  • 28
    McGory RW, Ishitani MB, Oliveira WM, Stevenson WC, McCullough C, Dickson R, et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with agressive passive immunization. Transplantation 1996: 61: 13581364.
  • 29
    Lowell JA, Burgess S, Shenoy S, Curci JA, Peters M, Howard T. Mercury poisoning associated with high dose hepatitis B immune globulin administration after liver transplantation. Liver Transpl Surg 1996, 2: 475478.
  • 30
    Mentha G, Giostra E, Negro F, Rubbia-Brandt L, Huber O, Hadengue A, et al. High-titered anti-HBs fresh frozen plasma for immunoprophylaxis against hepatitis B virus recurrence after liver transplantation. Transplant Proc 1997; 29: 23692373.
  • 31
    Terrault NA, Vyas G. Hepatitis B immune globulin preparations and use in liver transplantation. Clin Liver Dis 2003; 7: 537550.
  • 32
    Galun E, Eren R, Safadi R, Ashour Y, Terrault N, Keefe EB, et al. Clinical evaluation (phase I) of a combination of two human monoclonal antibodies to HBV: Safety and antiviral properties. Hepatology 2002; 35: 673679
  • 33
    Jury of the International Consensus conference on Indications of Liver Transplantation. Consensus statement on indications for liver transplantation: Paris, June 22-23, 1993. Hepatology 1994; 20( Suppl): 63S68S.
  • 34
    Marcellin P, Samuel D, Areias J, Loriot MA, Arulnaden JL, Gigou M, et al. Pretransplant interferon treatment and recurrence of hepatitis B virus infection after liver transplantation for hepatitis B-related end-stage liver disease. Hepatology 1994: 19: 612.
  • 35
    Andreone P, Biselli M, Gramenzi A, Cursaro C, Morelli MC, Sama C, et al. Efficacy of lamivudine therapy for advanced liver disease in patients with precoce mutant hepatitis B virus infection awaiting liver transplantation. Transplantation 2002; 74: 11191124.
  • 36
    Grellier L, Mutimer D, Ahmed M, Brown D, Burroughs AK, Rolles K, et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996: 348: 12121215.
  • 37
    Villeneuve JP, Condreay LD, Willems B, Pommier-Layrargues G, Fenyves D, Bilodeau M, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000: 31: 207210.
  • 38
    Lo CM, Cheung ST, Lai CL, Liu CL, Ng IO, Yuen MF, et al. Liver transplantation in Asian patients with chronic hepatitis B using lamivudine prophylaxis. Ann Surg 2001: 233: 276281.
  • 39
    Seehofer D, Rayes N, Naumann U, Neuhaus R, Muller AR, Tullius SG, et al. Preoperative antiviral treatment and postoperative prophylaxis in HBV-DNA positive patients undergoing liver transplantation. Transplantation 2001: 72: 13811385.
  • 40
    Fontana R, Keeffe E, Carey W, Fried M, Reddy R, Kowdley KV, et al. Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B. Liver Transpl 2002: 8: 433439.
  • 41
    Yao FY, Bass NM. Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection. J Hepatol 2000: 33: 301307.
  • 42
    Kapoor D, Guptan RC, Wakil SM, Kazim SN, Kaul A, Agarwal SR, et al. Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis. J Hepatol 2000: 33: 308312.
  • 43
    Stärkel P, Horsmans Y, Geubel A, Ciccarelli O, Goubau P, Rahier J, Lerut J. Favorable outcome of orthotopic liver transplantation in a patient with subacute liver failure due to emergence of a hepatitis B YMDD escape mutant virus. J Hepatol 2001: 35: 679681.
  • 44
    Saab S, Kim M, Wright T, Han SH, Martin P, Busuttil RW. Successful orthotopic liver transplantation for lamivudine-associated YMDD mutant hepatitis B virus. Gastroenterology 2000: 119: 13821384.
  • 45
    Marcellin P, Chang TT, Lim GS, Tong MJ, Sievert W, Shiffman ML, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 808816.
  • 46
    Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003; 348: 800807
  • 47
    Perrillo R, Schiff E, Yoshida E, Staler A, Hirsch K, Wright T, et al. Adefovir dipivoxil for the treatment of Lamivudine-resistant hepatitis B mutants. Hepatology 2000: 32: 129134.
  • 48
    Perillo R, Hann HW, Mutimer D, Willems B, Leung N, Lee WM, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004; 126: 8190.
  • 49
    Peters MG, Hann HW, Martin P, Heathcote J, Buggisch P, Rubin R, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004; 126: 91101.
  • 50
    Angus P, Vaughan R, Xiong S, Yang H, Delaney W, Gibbs C, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003; 125: 292297.
  • 51
    Villeneuve JP, Durantel D, Durantel S, Westland C, Xiong S, Brosgart CL, et al. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol 2003: 39: 10851089.
  • 52
    Yang H, Westland CE, Delaneey WE, Heathcote EJ, Ho V, Fry J, et al. Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. Hepatology 2002; 36: 464473.
  • 53
    Zoulim F. Treatment of pre- and post-liver transplantation HBV infection: Should we aim at combination therapy? Hepatology 2003; 28: 13531355.
  • 54
    Levine S, Hernandez D, Yamanaka G, Zhang S, Rose R, Weinheimer S, Colonno RJ. Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrob Agents Chemother 2002; 46: 25252532.
  • 55
    Van Bömmel F, Wünsche T, Mauss S, Reinke P, Bergk A, Schürmann D, et al. Comparaison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 2004; 40: 14211425.
  • 56
    Seigneres B, Pichoud C, Martin P, Furman P, Trepo C, Zoulim F. Inhibitory activity of dioxolane purine analogues on wild-type and lamivudine-resistant mutants of hepadnaviruses. Hepatology 2002; 36: 710722.
  • 57
    Lai CC, Lim S, Brown N, Zhou XJ, Lloyd D, Lee YM, et al. A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection. Hepatology 2004; 40: 719726.
  • 58
    Mutimer D, Dusheiko G, Barrett C, Grellier L, Ahmed M, Anschuetz G, et al. Lamivudine without HBIG for prevention of graft reinfection by hepatitis B: Long-term follow-up. Transplantation 2000; 70: 809815.
  • 59
    Malkan G, Cattral M, Humar A, Al Asghar H, Greig PD, Hemming AW, et al. Lamivudine for hepatitis B in liver transplantation. Transplantation 2000: 69: 14031407.
  • 60
    Mutimer D, Pillay D, Shields P, Cane P, Ratcliffe D, Martin B, et al. Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient. Gut 2000: 46: 107113.
  • 61
    Dickson R, Terrault N, Ishitani M, Reddy R, Sheiner P, Soldevilla-Pico C, et al. The effect of hepatitis B replication status on hepatitis B immunoglobulin dose requirements and pharmacokinetics in liver transplantation for hepatitis B virus [abstract]. Hepatology 2004; 40: A190.
  • 62
    Han SH, Martin P, Edelstein M, Hu R, Kunder G, Holt C, et al. Conversion from intravenous to intramuscular hepatitis B immune globulin in combination with lamivudine is safe and cost-effective in patients receiving long-term prophylaxis to prevent hepatitis B recurrence after liver transplantation. Liver Transpl 2003; 9: 182187.
  • 63
    Sanchez-Fueyo A, Rimola A, Grande L, Costa J, Mas A, Navasa M, et al. Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: A new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation. Hepatology 2000: 31: 496501.
  • 64
    Sanchez-Fueyo A, Martinez-Bauer E, Rimola A. Hepatitis B vaccination after liver transplantation. Hepatology 2002: 36: 257.
  • 65
    Angelico M, Di Paolo D, Trinito M, Petrolati A, Araco A, Zazza S, et al. Failure of a reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis. Hepatology 2002: 35: 176181.
  • 66
    Bienzle U, Günther M, Neuhaus R, Vandepapeliere P, Vollmar J, Lun A, Neuhaus P. Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B-related disease. Hepatology 2003: 38: 811819.
  • 67
    Albeniz Arbizu E, Barcena Marugan R, Oton Nieto E, Carrera Alonso E, Garcia Gonzalez M, Moreno Garcia J, et al. Prophylaxis of recurrent hepatitis B virus by vaccination after liver transplant: Preliminary results. Transplant Proc 2003; 35: 18481849.
  • 68
    Dodson SF, De Vera ME, Bonham CA, Geller DA, Rakela J, Fung JJ, et al. Lamivudine after hepatitis B immune globulin is effective in preventing hepatitis B recurrence after liver transplantation. Liver Transpl 2000: 6: 434439.
  • 69
    Naoumov NV, Lopes AR, Burra P, Caccamo L, Iemmolo RM, De Man RA, et al. Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation. J Hepatol 2001: 34: 888894.
  • 70
    Buti M, Mas A, Prieto M, Casafont F, Gonzalez A, Miras M, et al. A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation. J Hepatol 2003; 38: 811817.
  • 71
    Manzarbeitia C, Reich D, Ortiz J, Rothstein K, Araya V, Munoz S. Safe use of liver donors with positive hepatitis B core antibody. Liver Transpl 2002; 8: 556561.
  • 72
    Jilg W, Hottentrager B, Weinberger K, Schlottmann K, Frick E, Holstege A, et al. Prevalence of markers of hepatitis B in the adult German population. J Med Virol 2001; 63: 96102.
  • 73
    Garcia-Fulgueiras A, Tormo MJ, Rodriguez T, Perez-Flores D, Chirlaque D, Navarro C. Prevalence of hepatitis B and C markers in the south-east of spain: An unlinked community-based serosurvey of 2003 adults. Scand J Infect Dis 1996; 28: 1720.
  • 74
    Turner D, Zuckerman M, Alexander G, Waite J, Wreghitt T. Risk of inappropriate exclusion of organ donors by introduction of hepatitis B core antibody testing. Transplant 1997; 63: 775777.
  • 75
    Prieto M, Gomez MD, Berenguer M, Cordoba J, Rayon J, Pastor M, et al. De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an aera with high prevalence of anti-HBc positivity in the donor population. Liver Transpl 2001; 7: 5158.
  • 76
    Dickson R, Everhart J, Lake JR, Wei Y, Seaberg E, Wiesner R, et al. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. Gastroenterology 1997; 113: 11681174.
  • 77
    Douglas D, Rakela J, Wright T, Krom R, Wiesner R. The clinical course of transplantation-associated de novo hepatitis B infection in the liver transplant recipient. Liver Transpl Surg 1997; 3: 105111.
  • 78
    Roque-Afonso AM, Feray C, Samuel D, Simoneau D, Roche B, Emile JF, et al. Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBc positive donors. Gut 2002; 50: 9599.
  • 79
    Roche B, Samuel D, Gigou M, Feray C, Virot V, Schmets L, et al. De novo and apparent de novo hepatitis B virus infection after liver transplantation. J Hepatol 1997; 26: 517526.
  • 80
    Uemoto S, Sugiyama K, Marusawa H, Inomata Y, Asonuma K, Egawa H, et al. Transmission of hepatitis B virus from core antibody positive donors in living related liver transplants. Transplantation 1998; 65: 494499.
  • 81
    Dodson S, Bonham C, Geller D, Cacciarelli T, Rakela J, Fung J. Prevention of de novo hepatitis B infection in recipients of hepatic allografts from anti HBc-positive donors. Transplantation 1999; 68: 10581061.
  • 82
    Yu AS, Vierling J, Colquhoun S, Arnaout W, Chan C, Khanafshar E, et al. Transmission of hepatitis B virus infection from hepatitis B core antibody-positive liver allografts is prevented by lamivudine therapy. Liver Transpl 2001; 7: 513517.
  • 83
    Chang SH, Suh KS, Yi NJ, Choi SH, Lee HJ, Seo JK, Lee KU. Active immunization against de novo hepatitis B virus infection in pediatric patients after liver transplantation. Hepatology 2003; 37: 13291334.
  • 84
    Terrault NA, Holland C, Ferrell L, Hahn JA, Lake JR, Roberts JP, et al. Interferon alpha for recurrent hepatitis B infection after liver transplantation. Liver Transplant Surg 1996; 2: 132138.
  • 85
    Gish RG, Lau JYN, Brooks L, Fang JW, Steady SL, Imperial JC, et al. Ganciclovir treatment of hepatitis B virus (HBV) infection in liver transplant patients. Hepatology 1996; 23: 17.
  • 86
    Roche B, Samuel D, Gigou M, Feray C, Virot V, Majno P, et al. Long-term Ganciclovir therapy for hepatitis B virus infection after liver transplantation. J Hepatol 1999; 31: 584592.
  • 87
    Rayes N, Seehofer D, Hopf U, Neuhaus R, Naumann U, Bechstein WO, Neuhaus P. Comparison of famciclovir and lamivudine in the long-term treatment of hepatitis B infection after liver transplantation. Transplantation 2001; 71: 96101.
  • 88
    Roche B, Samuel D, Roque AM, Feray C, Petit AM, Vasseur B, et al. Lamivudine therapy for HBV infection after liver transplantation [abstract]. J Hepatol 1999; 30: 78.
  • 89
    Nery JR, Weppler D, Rodriguez M, Ruiz P, Schiff ER, Tzakis AG. Efficacy of lamivudine in controlling hepatitis B virus recurrence after liver transplantation. Transplantation 1998; 65: 16151621.
  • 90
    Ben-Ari Z, Mor E, Shapira Z, Tur-Kaspa R. Long-term experience with lamivudine therapy for hepatitis B virus infection after liver transplantation. Liver Transplant 2001; 7: 113117.
  • 91
    Andreone P, Caraceni P, Grazi GL, Belli L, Milandri G, Ercolani G, et al. Lamivudine treatment for acute hepatitis B after liver transplantation. J Hepatol 1998; 29: 985989.
  • 92
    Fischer L, Sterneck M, Zöllner B, Rogiers X. Lamivudine improves the prognosis of patients with hepatitis B after liver transplantation. Transplant Proc 2000; 32: 21282130.
  • 93
    Fontana RJ, Hann HW, Wright T, Everson G, Baker A, Schiff E, et al. A multicenter study of lamivudine treatment in 33 patients with hepatitis B after liver transplantation. Liver Transpl 2001; 6: 504510.
  • 94
    Neff GW, Nery J, Lau D, O'Brien C, Duncan R, Shire N, et al. Tenofovir therapy for lamivudine resistance following liver transplantation. Ann Pharmacother 2004; 12: 19992004.
  • 95
    Chayama K, Suzuki Y, Kobayashi M, Tsubota A, Hashimoto M, Miyano Y, et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 1998; 27: 17111716.
  • 96
    Peters MG, Singer G, Howard T, Jacobsmeyer S, Xiong X, Gibbs C, et al. Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient: Durable response after orthotopic liver transplantation on adefovir dipivoxil and hepatitis B immune globulin. Transplantation 1999; 68: 19121914.
  • 97
    Mutimer D, Feraz-Neto BH, Harrison R, O'Donnell K, Shaw J, Cane P, Pillay D. Acute liver graft failure due to emergence of lamivudine resistant hepatitis B virus: Rapid resolution during treatment with adefovir. Gut 2001; 49: 860863.
  • 98
    Walsh KM, Woodall T, Lamy P, Wight D, Bloor S, Alexander GJ. Successful treatment with adefovir dipivoxil in a patient with fibrosing cholestatic hepatitis and lamivudine resistant hepatitis B virus. Gut 2001; 49: 436440.
  • 99
    Shakil AO, Lilly L, Angus P, Gerken G, Thomas N. Entecavir reduces viral load in liver transplant patients who have failed prophylaxis or treatment for hepatitis B [abstract]. Hepatology 2001; 34( Suppl): 619.